Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
Item | Description | The company |
---|---|---|
EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Becton, Dickinson & Co. EBITDA decreased from 2019 to 2020 but then increased from 2020 to 2021 exceeding 2019 level. |
Enterprise Value to EBITDA Ratio, Current
Selected Financial Data (US$ in millions) | |
Enterprise value (EV) | 89,222) |
Earnings before interest, tax, depreciation and amortization (EBITDA) | 4,984) |
Valuation Ratio | |
EV/EBITDA | 17.90 |
Benchmarks | |
EV/EBITDA, Competitors1 | |
Abbott Laboratories | 21.76 |
Cigna Group | 10.71 |
CVS Health Corp. | 6.70 |
Elevance Health Inc. | 7.79 |
Intuitive Surgical Inc. | 83.53 |
Medtronic PLC | 16.39 |
UnitedHealth Group Inc. | 14.59 |
EV/EBITDA, Sector | |
Health Care Equipment & Services | 15.87 |
EV/EBITDA, Industry | |
Health Care | 16.01 |
Based on: 10-K (reporting date: 2021-09-30).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | ||
---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||
Enterprise value (EV)1 | 84,640) | 80,969) | 89,200) | 85,173) | 55,792) | 45,755) | |
Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 4,984) | 3,667) | 4,068) | 3,857) | 2,585) | 2,576) | |
Valuation Ratio | |||||||
EV/EBITDA3 | 16.98 | 22.08 | 21.93 | 22.08 | 21.58 | 17.76 | |
Benchmarks | |||||||
EV/EBITDA, Competitors4 | |||||||
Abbott Laboratories | 17.42 | 25.99 | 21.70 | — | — | — | |
Cigna Group | 9.06 | 6.31 | 8.42 | — | — | — | |
CVS Health Corp. | 10.41 | 8.56 | 9.43 | — | — | — | |
Elevance Health Inc. | 10.05 | 7.57 | 9.05 | — | — | — | |
Intuitive Surgical Inc. | 44.54 | 59.12 | 37.53 | — | — | — | |
Medtronic PLC | 24.41 | 17.92 | 16.01 | — | — | — | |
UnitedHealth Group Inc. | 17.39 | 13.39 | 13.82 | — | — | — | |
EV/EBITDA, Sector | |||||||
Health Care Equipment & Services | 15.40 | 13.12 | — | — | — | — | |
EV/EBITDA, Industry | |||||||
Health Care | 13.87 | 16.50 | — | — | — | — |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
3 2021 Calculation
EV/EBITDA = EV ÷ EBITDA
= 84,640 ÷ 4,984 = 16.98
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Becton, Dickinson & Co. EV/EBITDA ratio increased from 2019 to 2020 but then decreased significantly from 2020 to 2021. |